MetaCap

RenovoRx Inc. Company Profile

NASDAQ: RNXTHealthcareBiotechnologyUSD

1.33-0.04 (-2.92%)

At close: Oct 8, 4:00 PM ET · Delayed 15 min

RenovoRx at a glance

RenovoRx Inc. (NASDAQ: RNXT) is a Biotechnology company in the Healthcare sector headquartered in Mountain View, CA. RenovoRx is led by Mr. Shaun R. Bagai and employs about 17 people. The company's shares have traded publicly since 2021.

At a market capitalization of $60.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001574094, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does RenovoRx do?

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Business description based on the company's public filings.

Company information

Legal name
RenovoRx Inc.
Ticker
NASDAQ: RNXT
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shaun R. Bagai
Employees
17
Headquarters
2570 West El Camino Real, Mountain View, CA, United States
Phone
650 284 4433
Website
renovorx.com
IPO year
2021
Market cap
$60.02M
SEC CIK
0001574094

Companies similar to RenovoRx

RNXT peer companies
CompanyPrice% ChgMarket capCompare
MREOMereo BioPharma Group plc ADR0.3752+6.35%$59.92Mvs RNXT
GOSSGossamer Bio Inc.9.88-2.95%$60.43Mvs RNXT
KLRSKalaris Therapeutics Inc.2.50-2.34%$59.51Mvs RNXT
XLOXilio Therapeutics Inc.9.010.00%$59.29Mvs RNXT
IBIOiBio Inc.0.92-8.91%$59.16Mvs RNXT
ELOXEloxx Pharmaceuticals Inc.15.18+2.02%$61.27Mvs RNXT
BOLDBoundless Bio Inc.2.58-2.27%$58.69Mvs RNXT
PLRXPliant Therapeutics Inc.1.00+1.01%$61.92Mvs RNXT

Related